Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings miss

  • 📰 wjxt4
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 63%

Business Noticias

España Últimas Noticias,España Titulares

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations.

LIVE: Secretary of State Brad Raffensperger gives update on early voting after Georgians break 3 million mark

Read full article: LIVE: Secretary of State Brad Raffensperger gives update on early voting after Georgians break 3 million markEstranged couple accused in murder-for-hire plot appears in court for pre-trial hearingKeep your drink cold longer with these tumblers. See more Insider Deals here.Looking to save on items for your home, road trip and wardrobe? We've got the latest Insider Deals to share!FILE - This April 26, 2017 file photo shows the Eli Lilly & Co.

Leerink Partners analyst David Risinger said separately that although Lilly’s results were disappointing, he is keeping his “outperform” rating on the stock. He noted that Lilly “is just getting started in commercializing obesity products globally.”

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 246. in ES
 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.

España Últimas Noticias, España Titulares